- Home
- TDUP vs FATE Comparison
TDUP vs FATE Comparison
Compare TDUP & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDUP | FATE |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 260.0M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TDUP | FATE |
|---|---|---|
| Price | $1.40 | $1.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $7.24 | $5.74 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 11-04-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.36 | 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $310,813,000.00 | $6,646,000.00 |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $10.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.53 | N/A |
| 52 Week Low | $1.91 | $0.95 |
| 52 Week High | $8.76 | $3.23 |
Technical Indicators
Market Signals| Indicator | TDUP | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 47.12 |
| Support Level | $2.09 | $1.78 |
| Resistance Level | $2.52 | $2.15 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 57.15 | 70.83 |
Price Performance
Historical ComparisonAbout TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for apparel, shoes, and accessories. The company's marketplaces have enabled buyers in the United States ("U.S.") to browse and purchase resale items principally for apparel, shoes, and accessories across a range of price points. The company's revenue is principally from the sale of secondhand apparel, shoes, and accessories on behalf of sellers.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.